Detalhe da pesquisa
1.
Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents.
Oral Dis
; 26(5): 955-966, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32011077
2.
Microsatellite Instability Is Insufficiently Used as a Biomarker for Lynch Syndrome Testing in Clinical Practice.
JCO Precis Oncol
; 8: e2300332, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38271656
3.
The Impact of Enhanced Recovery after Surgery Protocol Implementation on Postoperative Pain Management in the Era of Opioid Crisis: The Postchemotherapy Open RPLND Experience.
Curr Cancer Drug Targets
; 23(11): 910-916, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37170984
4.
Lack of prognostic significance of p16 and p27 after radical prostatectomy in hormone-naïve prostate cancer.
J Negat Results Biomed
; 11(1): 2, 2012 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-22221586
5.
CD10 is inversely associated with nuclear factor-kappa B and predicts biochemical recurrence after radical prostatectomy.
Urol Int
; 88(2): 158-64, 2012.
Artigo
em Inglês
| MEDLINE | ID: mdl-22286396
6.
Bortezomib reverses the proliferative and antiapoptotic effect of neuropeptides on prostate cancer cells.
Int J Urol
; 19(6): 565-74, 2012 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-22324515
7.
Inverse baseline expression pattern of the NEP/neuropeptides and NFκB/proteasome pathways in androgen-dependent and androgen-independent prostate cancer cells.
Cancer Cell Int
; 11(1): 13, 2011 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-21569620
8.
Nonbacterial thrombotic (marantic) endocarditis in a patient with colorectal cancer.
Onkologie
; 33(8-9): 456-9, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-20838062
9.
The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 2: transcriptional regulation.
J Cell Mol Med
; 13(9B): 3019-31, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19522844
10.
The ubiquitin-proteasome system in cancer, a major player in DNA repair. Part 1: post-translational regulation.
J Cell Mol Med
; 13(9B): 3006-18, 2009 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-19522845
11.
Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma.
BJU Int
; 104(4): 456-60, 2009 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-19338544
12.
CT quantification of effects of thalidomide in patients with metastatic renal cell carcinoma.
AJR Am J Roentgenol
; 189(2): 378-85, 2007 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-17646464
13.
Phase II study of capecitabine single-agent therapy in patients with metastatic renal cell carcinoma.
Urol Oncol
; 24(6): 487-91, 2006.
Artigo
em Inglês
| MEDLINE | ID: mdl-17138128
14.
Thalidomide/estramustine/paclitaxel in metastatic androgen-independent prostate cancer.
Clin Genitourin Cancer
; 5(2): 144-9, 2006 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-17026803
15.
Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate.
J Clin Oncol
; 20(14): 3072-80, 2002 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12118020
16.
Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma.
J Clin Oncol
; 20(13): 2965-70, 2002 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12089226
17.
Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial.
J Clin Oncol
; 21(4): 679-89, 2003 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12586806
18.
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
J Clin Oncol
; 22(11): 2108-21, 2004 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15169797
19.
Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts.
Clin Cancer Res
; 9(7): 2587-97, 2003 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-12855635
20.
Treatment of refractory urothelial carcinoma with alternating paclitaxel, methotrexate, cisplatin (TMP) and 5-fluorouracil, alpha-interferon, cisplatin (FAP).
Urol Oncol
; 21(5): 342-8, 2003.
Artigo
em Inglês
| MEDLINE | ID: mdl-14670540